$0.60 EPS Expected for Abbott Laboratories (ABT)

July 18, 2017 - By Adrian Mccoy

 $0.60 EPS Expected for Abbott Laboratories (ABT)
Investors sentiment increased to 1.01 in Q4 2016. Its up 0.05, from 0.96 in 2016Q3. It improved, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported.
Capstone Investment Advsr Ltd Co stated it has 0.23% in Abbott Laboratories (NYSE:ABT). Ronna Sue Cohen, a Utah-based fund reported 83,841 shares. Bbva Compass Commercial Bank Inc holds 0.58% or 215,050 shares. Independent Port Consultants accumulated 3,128 shares or 0.04% of the stock. Perkins Coie Tru invested in 268 shares or 0.01% of the stock. Profund Advisors Ltd Limited Liability Company owns 55,341 shares. Teachers Ins & Annuity Association Of America accumulated 0.36% or 271,600 shares. L And S Advisors Incorporated stated it has 0.11% in Abbott Laboratories (NYSE:ABT). 35,766 were reported by Cleararc Cap Incorporated. 135,799 are held by Engines Advsr Llc. Capital Planning Advisors Ltd, a California-based fund reported 54,109 shares. Woodstock Corp stated it has 121,188 shares or 0.94% of all its holdings. Northern invested in 23.00 million shares. 17,455 are held by Aureus Asset Mgmt Limited Liability Corporation. Chevy Chase Incorporated has 1.35M shares for 0.28% of their portfolio.

Since January 31, 2017, it had 1 insider buy, and 20 insider sales for $8.46 million activity. $6,567 worth of Abbott Laboratories (NYSE:ABT) was sold by MANNING JOSEPH J. $34,240 worth of stock was sold by Contreras Jaime on Friday, March 31. Fussell Stephen R bought $497,394 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, January 31. Shares for $146,200 were sold by ALLEN HUBERT L on Monday, February 13. $78,434 worth of Abbott Laboratories (NYSE:ABT) shares were sold by YOOR BRIAN B. On Tuesday, February 28 the insider BIRD ROGER sold $72,069. Another trade for 1,912 shares valued at $86,068 was made by Mason Heather L on Tuesday, February 28.

Wall Street await Abbott Laboratories (NYSE:ABT) to release earnings on July, 19. Analysts forecast EPS of $0.60, up exactly $0.05 or 9.09 % from 2014’s $0.55 EPS. The expected ABT’s profit could reach $1.04B giving the stock 20.32 P/E in the case that $0.60 earnings per share is reported. After posting $0.48 EPS for the previous quarter, Abbott Laboratories’s analysts now forecast 25.00 % EPS growth. The stock decreased 0.31% or $0.15 on July 17, reaching $48.76. About shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since July 18, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 20 analysts covering Abbott Laboratories (NYSE:ABT), 12 have Buy rating, 0 Sell and 8 Hold. Therefore 60% are positive. Abbott Laboratories has $90 highest and $4 lowest target. $49.81’s average target is 2.15% above currents $48.76 stock price. Abbott Laboratories had 59 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Thursday, June 29 by Jefferies. As per Friday, October 9, the company rating was maintained by RBC Capital Markets. The stock of Abbott Laboratories (NYSE:ABT) has “Equal-Weight” rating given on Monday, January 4 by Morgan Stanley. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, January 29. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) rating on Wednesday, April 19. Stifel Nicolaus has “Buy” rating and $49 target. Deutsche Bank maintained the shares of ABT in report on Saturday, August 29 with “Buy” rating. RBC Capital Markets maintained the shares of ABT in report on Wednesday, March 1 with “Outperform” rating. The company was maintained on Tuesday, March 15 by Jefferies. Jefferies maintained the shares of ABT in report on Tuesday, June 14 with “Buy” rating. The firm has “Buy” rating given on Thursday, August 27 by Wells Fargo.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $84.35 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 54.13 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Twst.com which released: “Abbott Laboratories: Abbott Commences Cash Tender Offer for All Outstanding …” on July 17, 2017, also Chicagotribune.com with their article: “Diabetics can avoid finger pricks with new app from Abbott, Silicon Valley partner” published on July 13, 2017, Nasdaq.com published: “Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2017” on July 11, 2017. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Reuters.com and their article: “BRIEF-Abbott Laboratories names John Stratton to its board” published on June 29, 2017 as well as Realmoney.Thestreet.com‘s news article titled: “Abbott Laboratories Is Set for Another Breakout” with publication date: July 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.